Insmed reports preliminary 2024 ARIKAYCE revenue of $363.7M, sets 2025 guidance of $405-425M

INSMED Inc

Preliminary 2024 ARIKAYCE global net sales of $363.7M, up 19% YoY; 2025 guidance $405-425M (11-17% growth)
Brensocatib NDA for bronchiectasis submitted to FDA in Dec 2024; U.S. launch expected Q3 2025 under priority review
Phase 2 TPIP in PAH fully enrolled (102 patients); topline data now expected mid-2025
ENCORE trial for ARIKAYCE in MAC lung disease enrolled 425 patients (exceeding 400 target); topline Q1 2026
IND cleared for DMD gene therapy INS1201; first patient dosing anticipated H1 2025

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.